Back to search

Institutes outside Greece

Making the most of a few small population clinical trials

Abstract

dc:description

”Patients in rare diseases should be entitled to the same quality of treatment as other patients”. The recent implementation of international and national strategy plans for rare diseases has led to an incredible increase of data quantity. As is generally known, such data become available through various sources, for instance; claim databases, e-health records, national registries and experimental studies. Information provided from either of these sources can be utilized during the evaluation of a (new) treatment. Depending on the stakeholder, we often need to evaluate multiple questions; such as, (i) do the treatment’s risks outweigh the added benefit?, (ii) does the treatment’s added benefit outweigh the costs?, (iii) does the treatment help each and every individual patient or (iv) does the treatment actually work? The latter question is often evaluated by a randomized controlled trial. According to Orphanet, more than 1829 trials among 29 countries focus on more than 800 rare conditions. This number of historical and ongoing trials explains the urgent need for evaluating and developing tailor-made statistical methods for small populations and so far, three recent large European projects have responded to materializing this need. Statisticians, methodologists, clinicians and patients, all interested parties recognize the specific issue of the increased presence of heterogeneity among the patients that suffer from a specific rare condition. Heterogeneity introduces further complexity during the evaluation of a (new) treatment within a single randomized clinical trial, where the limited availability of sample sizes restricts practitioners from evaluating subgroups of patients within each trial. Although counter-intuitive, as sample sizes per trial become smaller, conducting more than one trial might provide a clearer overview of the treatment efficacy. Orphan drugs for rare diseases are often investigated through multinational randomized controlled trials. Investigations in such a global setting may lead to increased inconsistency, given that the clinical expertise, the standards of care and the used facilities vary e.g. between each country. Non-homogeneous data makes single trials less reliable, which means that the need to explore synthesis methods of a few small studies through meta-analysis is even more necessary. This thesis focuses on the latter.

Degree

thesis:*
Grantor dc:publisher
Institutes outside Greece
Year dc:date
2020

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Pateras, Konstantinos
  • Πατέρας, Κωνσταντίνος

Subjects

dc:subject × 27

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/52102

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Pateras, Konstantinos; Πατέρας, Κωνσταντίνος. Making the most of a few small population clinical trials. Institutes outside Greece, 2020. http://hdl.handle.net/10442/hedi/52102